About iPSC Regenerative Medicine

Induced pluripotent stem cells (iPSCs) are established by introducing several factors to somatic cells such as skin cells. iPSCs can differentiate into the cells of a various tissues or organs (pluripotency) and grow indefinitely (proliferation). The objective of iPSC regenerative medicine is to restore cellular function by replacing dysfunctional tissues with cell therapy medicines, which are prepared via a differentiation process (a technique used to artificially change cells into those having specific functions),
and which have the same functions as healthy human tissues.

Replace damaged cells with regular cells

Business Structure & Partners

In order to develop the new industry of regenerative medicine using iPSCs, we at Healios aim to create a system that spans the entire value chain, from production to sales, and are nurturing affiliate relationships with various universities, research institutions, and business partners.

IPSC Regenerative Medicine Field Business Partners

Pipeline in the Field of iPSC Regenerative Medicine

【Ophthalmology Area】

Please refer to the page “About Age-Related Macular Degeneration (AMD)” involving transplantation of iPSC-derived retinal pigment epithelial (RPE) cells as an iPSC regenerative medicine.

Development Code Indication Market Pre-clinical test Apply-approve On the Market Progress Status
HLCR011 Wet AMD Japan
Transplantation conducted
under Clinical research(*1)
Undergoing preparation for clinical trial
Development Code Indication Market Pre-clinical test Phase I Trial Phase II Trial Phase III Trial Apply-approve On the Market Progress Status
HLCR012 Dry AMD US
CRADA with NEI
HLCR012 Dry AMD EU
Global trial under consideration based on US phase III trial
  1. “Clinical research of transplantation of induced pluripotent stem cells – derived retinal pigment epithelium (RPE) cells for exudative age-related macular degeneration (AMD)” conducted by RIKEN etc.

【Liver Disease】

Please refer to the page “About Liver Disease” involving a technology to create functional human organs using pluripotent stem cells (such as iPSCs).

Development Code Indication Market Pre-clinical test Apply-approve On the Market Progress Status
HLCL041 Metabolic Liver Disease Japan
ONL established